SpliceHetero: An information theoretic approach for measuring spliceomic intratumor heterogeneity from bulk tumor RNA-seq

Minsu Kim², Sangseon Lee², Sangsoo Lim¹, Sun Kim*¹,²,³

¹ Department of Computer Science and Engineering, Seoul National University, Seoul, 08826, Korea,
² Interdisciplinary Program in Bioinformatics, Seoul National University, Seoul, 08826, Korea,
³ Bioinformatics Institute, Seoul National University, Seoul, 08826, Korea

* sunkim.bioinfo@snu.ac.kr

Abstract

Motivation

Intratumor heterogeneity (ITH) represents the diversity of cell populations that make up cancer tissue. The level of ITH in a tumor is usually measured by a genomic variation profile, such as copy number variation and somatic mutation. However, a recent study has identified ITH at the transcriptome level and suggested that ITH at gene expression levels is useful for predicting prognosis. Measuring ITH levels at the spliceome level is a natural extension. There are serious technical challenges in measuring spliceomic ITH (sITH) from bulk tumor RNA sequencing (RNA-seq) due to the complex splicing patterns.

Results

We propose an information-theoretic method to measure the sITH of bulk tumors to overcome the above challenges. This method has been extensively tested in experiments using synthetic data, xenograft tumor data, and TCGA pan-cancer data. As a result, we showed that sITH is closely related to cancer progression and clonal heterogeneity, along with clinically significant features such as cancer stage, survival outcome and PAM50 subtype. As far as we know, it is the first study to define ITH at the spliceome level. This method can greatly improve the understanding of cancer spliceome and has great potential as a diagnostic and prognostic tool.

Introduction

Intratumor heterogeneity (ITH) represents the diversity of cell populations that make up cancer tissue [1]. This results from a subclone diversification process during cancer progression, which is considered a form of Darwinian evolutionary process [2]. The level of ITH reflects the...
genetic diversity of bulk tumors, which generally has a negative impact on prognosis. An explanation for this trend is that the genetic diversity provided by ITH can be an accelerator of somatic cell evolution that helps cancer cells acquire a malignant phenotype [3, 4, 5, 6]. Studies have been published that measure the level of ITH in bulk tumors in the whole genome level [7, 8, 9].

In a recent study by Morris et al. [10], the ITH of each cancer sample was calculated using genomic features such as copy number variation (CNV) and somatic mutation. Then, the relationship between the ITH of each cancer sample and various clinical characteristics was tested. They concluded that the level of ITH in each cancer sample was significantly associated with the molecular, pathological, and clinical characteristics including prognosis. Other studies are supporting the results of Morris et al. [11, 12].

Related works

ITH can be deduced using molecular profiles extracted from genomic, epigenomic and transcriptomic data such as whole-genome sequencing (WGS), CNVs, bisulfite-seq, and RNA-seq data. Approaches using each domain have been used to assess the level of ITH in cancer tissues and to identify molecular features associated with tumor evolution (Table 1). For example, two ITH studies using genomic variation have revealed somatic mutations that are closely related to tumor evolution in various types of cancer [13, 14]. Methyloic and transcriptomic (gene-expression) methods for measuring ITH in bulk tumors were developed and identified important molecular features [15, 16].

Genome-level ITH has been extensively studied using bulk tumor sequencing data. ABSOLUTE [13] is a genomic ITH (gITH) model that uses somatic mutations and CNV profiles of bulk tumors to infer ITH. ABSOLUTE estimated the optimal values of cancer purity and ploidy using a linear programming technique and then estimated the subclonal genome fractions (ie, ITH). A slightly different approach was used in PyClone [14]. PyClone used the Bayesian model to define the generative relationship between the number of subclones and the observed genomic variation and then used the Bayesian clustering algorithm to select the optimal number of subclones that best fit the observed data.

Recently, an ITH model using a methylation profile was developed. This model, proposed by Mazor et al. [16], used a mathematical modeling approach similar to the genomic data based model. DNA methylation does not alter the DNA sequence but is linked to genomic DNA. Thus, the DNA methylation pattern has similar characteristics to the genomic variants.

### Table 1. Description of each approach using various molecular domains.

| Domain | Variation | Method | Findings |
|--------|-----------|--------|----------|
| Genomic | CNVs Somatic mutations | Mathematical modeling | Suggesting CDK12 as a candidate TSG in ovarian carcinoma [13] |
| Methyloic | Methylation | Mathematical modeling | Association between mutations in chromatin modifiers like SMARCA4, BAP and methyloic ITH [16] |
| Transcriptomic | Gene expression | Information theory | Suggesting that cell cycle related pathways have significant contribution to increasing heterogeneity on the network during clonal evolution [15] |
| Spliceomic | Alternative splicing | None | None |

1. The Domains column represents the domain data used in each approach.
2. The Variation column represents the genetic variation that each approach uses to construct the model.
3. The Method column indicates the type of algorithm each approach uses to build the model.
4. The Findings column explains the results revealed using each approach.

https://doi.org/10.1371/journal.pone.0223520.t001
For example, when bisulfite-seq is used, methylation base detection is similar to somatic mutation detection.

A transcriptome-level ITH model was recently developed [15]. They used information theory to estimate ITH in bulk tumors. They proposed an interesting idea to consider ITH as the difference in gene expression distribution between normal tissue and bulk tumors. They first used a curated database of molecular pathways, such as the KEGG database [17], to construct a template network and construct a probability distribution for each pathway. The divergence between normal tissue and bulk tumor samples is then calculated by the average Jensen-Shannon Divergence (JSD) of each probability distribution for each pathway. This divergence was considered to be transcriptomic ITH (tITH) for each sample and was found to be related to clonal evolution and prognostic features.

**Motivation**

Splicing variations have been regarded as important cancer drivers in various types of cancer [18, 19, 20, 21]. In 2018, Kahles et al. performed a pan-cancer level study that investigates the impacts of splicing variations on cancer progression [22]. They performed a systematic analysis of alternative splicing landscape across 8,705 cancer patients and found that many tumors contain numerous novel splicing junctions, which is not typically found in normal samples. And these novel junctions were identified as a class of potential neo-antigens. This means that the splicing variant of cancer cells can be an important factor in the evolution of the tumor. Other studies support the idea [20, 23].

The presence of intercellular spliceomic differences has also been proposed by numerous studies [24, 25]. A recent single-cell study showed that there is a clear difference in the use of isoforms in bone marrow-derived dendritic cells [26]. The clinical effect of spliceomic ITH (ie, sITH) has not been thoroughly studied because a systematic sITH model has not yet been developed.

Since Park et al. [15] proposed a pioneering model of ITH at the RNA level, the spliceomic ITH (ie, sITH) is naturally defined by adopting their method [15]. However, there are serious technical difficulties in applying their methods to sITH. First, the tITH model by Park et al. [15] requires a template network to generate probability distributions that are not available in our case. Also, a recent study has reported the widespread intron retention of cancer cells [27], suggesting that the isoform of cancer cells is very complex and not yet characterized. This means that a significant amount of unexpected splice junctions can be found in the cancer sample [28]. To handle these unexpected splice junctions, a transcriptome assembly is required to account for previously unknown isoforms. However, prevalent splice-site mutations [29] and short sequence reads in RNA-seq make it difficult to perform transcriptome assembly. Therefore, a new model is needed to avoid this difficulty and to measure sITH in bulk tumors.

The flow of subsequent manuscripts is as follows: 1) definition of the proposed model, 2) basic verification of the validity of the model, 3) performance verification of the model using synthetic data, 4) performance verification using xenograft tumor data, and 5) performance verification using TCGA pan-cancer data.

**Materials and methods**

In this study, we used bulk-tumor RNA-seq data to measure sITH. It is a technique that combines bulk sampling with short-read sequencing. A possible alternative for each part is single-cell analysis and single-molecule real-time sequencing (SMRT-seq). Single-cell analysis has been improved in terms of stability and efficiency and has been used in many biological studies. This technique is very useful for studying ITH because it provides a molecular profile of
every single cell in bulk tumors [30]. However, due to patient-to-patient heterogeneity, extensive analysis of a large group of patients is required to produce a reproducible cancer model. Thus, a single cell approach is not feasible in this case. Another technology, SMRT-seq, has received much attention because of its long read length and the advantage of being free from bias induced by cDNA amplification. However, sequencing errors in SMRT-seq are still a problem [31] and production costs are still very high. Currently, major cancer consortia such as TCGA produce only bulk tumor RNA-seq data. It is therefore difficult to obtain data with adequate clinical information using the SMRT-seq platform or single-cell platform. Thus, this study focused primarily on bulk-tumor RNA-seq.

Definition of the proposed model

As discussed in the previous section, transcript assembly in cancer is very difficult due to complex splicing patterns, noncanonical splice sites, and short-length sequence reads. So we decided to use a local analysis approach to avoid transcriptome assembly. Here, each RNA-seq read that supports each splicing event is collected and grouped by each intron region. (Fig 1). Spliced aligners such as RNA-STAR [32] align RNA reads with reference genome sequences and output mapped positions on chromosomes. Because RNA-seq reads are originated from mature mRNA transcripts, the spliced region remains a gap in the final alignment. The aligner

![Fig 1. Illustration of an intronic splicing unit.](https://doi.org/10.1371/journal.pone.0223520.g001)
collects the spliced gaps and organizes them into splice sites (i.e., the ends of the intron). As a result, the aligner lists the position of each splice site on the chromosome observed in a given RNA-seq and the number of supporting reads. The list of splice junctions extracted from the RNA-seq of each bulk tumor is the input data to construct our model (Fig 1).

Then we defined a local unit called an intronic splicing unit or splicing unit, which is defined as a collection of splicing events for each intron (Fig 1). In this scheme, splice junctions sharing a common splice site are grouped into a single unit. As in Fig 1, if three splice junctions are sharing a common splice site upstream and three alternate sites downstream, a splicing unit \( S \) consisting of \( A, B, \) and \( C \) can be defined. Where the input variable is defined by the junction count of \( A, B \) and \( C \) (i.e. \( \text{CNT}_S = (5, 3, 2) \), Eq 1). By dividing the sum of the total observations we can get the probability distribution for \( S \) (i.e. \( \text{P}_S = (0.5, 0.3, 0.2) \), Eq 1).

\[
P_k(i) = \frac{\text{CNT}_k(i)}{\sum_{j=1}^{N_k} \text{CNT}_k(j)}
\]  

Where \( \text{CNT}_k(i) \) represents the number of RNA-seq reads that support \( i \)-th alternative splice site in \( k \)-th splicing unit. \( P_k(i) \) is the fraction of RNA-seq reads that support the \( i \)-th splice site of the \( k \)-th splicing unit. \( N_k \) is the total number of alternative sites in \( k \)-th splicing unit.

Normal tissues are also known to have heterogeneity in the use of isoforms between cells [26]. To deal with this, we defined the spliceome ITH (i.e., sITH) as the distance from the normal tissue sample to the bulk tumor sample. By doing so, the model is expected to eliminate the innate heterogeneity that exists in normal tissues, leaving only the perturbations that occur during cancer progression. We used the Jensen-Shannon Divergence (JSD), which is defined by averaging bidirectional Kullback-Leibler Divergences (KLDs) from the introduced intermediate data points (Eq 2) [33, 34]. Then JSD gets the symmetric property and the metric value is limited from 0 to 1 (if you are using a base 2 log). JSD has been used in bioinformatics studies for its symmetric property [35, 36]. We defined input variables representing the distribution of isoform usage for each sample of each locus as a JSD-computable form (Eq 1).

JSD can be calculated for each intronic region (Eq 2). Because each input variable is intended to reflect the use of the splice site at each intronic region, the JSD between the two samples indicates how much the two samples differ in their use of the splice site in that intronic region. This distance is scaled from 0 to 1. Where 0 means that the splice site usage pattern is the same and 1 is completely different. After calculating the JSD for each splicing unit, a single indicator representing the ITH of entire spliceome is calculated by averaging the JSD of all units (Eq 5). We named this indicator as spliceomic intratumor heterogeneity (or sITH). The detailed calculation procedure is as follows.

\[
JSD(P_k, Q_k) = \frac{1}{2} (\text{KLD}(P_k||M_k) + \text{KLD}(Q_k||M_k))
\]  

\[
\text{KLD}(P_k||M_k) = -\sum_{i=1}^{N_k} P_k(i) \log \frac{P_k(i)}{M_k(i)}
\]  

\[
M_k(i) = \frac{1}{2} (P_k(i) + Q_k(i))
\]

\( JSD(P_k, Q_k) \) represents the Jensen-Shannon divergence between the two distributions \( P_k \) and \( Q_k \), where \( P_k \) and \( Q_k \) denote the splice-site usage distribution of the \( k \)-th splicing unit in samples \( P \) and \( Q \), respectively. Note that \( P_k \) and \( Q_k \) are defined in Eq 1. \( M_k \) represents the
intermediate distribution introduced between two distributions $P_k$ and $Q_k$ designed to calculate bi-directional KLD (Eq 4). $KLD(P_k || M_k)$ represents the Kullback-Leibler divergence of the distribution $P_k$ from $M_k$. There might be a case that two samples have different sets of splice sites. In that case, the pseudo-count is added to the splice site, which is not found in one sample, where the pseudo-count is calculated to be $1/100$ of the total number of reads in the corresponding splicing unit.

$$sITH(P, Q) = \frac{1}{L} \sum_{k=1}^{L} JSD(P_k, Q_k)$$ (5)

$sITH(P, Q)$ represents the increased sITH of a sample $P$ from the origin sample $Q$ to be compared. In the actual case, the target sample $P$ corresponds to a bulk tumor sample, and the origin sample $Q$ corresponds to a normal sample. In this case, $sITH(P, Q)$ may be called sITH of sample $P$ for convenience (Fig 2). $L$ represents the total number of splicing units (usually 20 ~ 30 thousands units found in human cancer tissue). Here, the two samples to be compared are pre-processed using the pseudo-counting described above to have the same number of splicing units for the compatibility issue. Therefore, the $i$-th splicing unit of samples $P$ and $Q$ represents the same intronic region.

**Basic verification of the validity of the model**

Before the full-scale analysis, we validated the local analysis approach described above. The key question is whether ITH measured in intron units can replace ITH measured in whole-transcript units. To do this, we prepared a simple experiment using synthetic data. First, 10 genes are randomly selected based on the NCBI RefSeq gene annotation [37]. RNA-seq samples with arbitrary isoform blending ratios were synthesized for these 10 selected genes. To simplify the problem, we simulated heterogeneity by selecting the longest isoform for each gene as the representative transcript and mixing the remaining isoforms at an arbitrary rate. Simulation of RNA-seq data was performed using WgSim, a well known NGS data synthesis tool (CMD: wgsim -e0 -r0 -R0 -X0 -a0 -A1 -d 500 -s 5) [38].

The whole-transcript ITH (ie $ITH_{transcript}$) of these RNA-seq samples was defined using Shannon’s entropy as Eq 6, which was proposed by Graf et al. [39]. For the same samples, we
define the intronic ITH (ie, $ITH_{intron}$) as Eq 7. We randomly selected 10 genes 10 times and randomly assigned 100 heterogeneity levels to each gene pool to synthesize a total of 1000 RNA-seq data. The correlation between $ITH_{transcript}$ and $ITH_{intron}$ calculated for the 1,000 samples was analyzed. The results are discussed in the "Results" section.

$$ITH_{transcript} = -\frac{1}{10} \sum_{g=1}^{10} \sum_{i=1}^{N_g} P_{gi} \log P_{gi}$$

Eq 6

$P_{gi}$ indicates the ratio of the i-th isoform of the g-th gene and implies the sequencing coverage ratio in the context of this analysis. $N_g$ indicates the number of isoforms of the g-th gene.

$$ITH_{intron} = -\frac{1}{L} \sum_{k=1}^{L} \sum_{i=1}^{N_k} P_{ki} \log P_{ki}$$

Eq 7

$P_{ki}$ is the selection ratio for the i-th splice site of the k-th intron unit, which means the read count ratio between splicing junctions. $N_k$ is the number of splice sites of the k-th intron unit. $L$ indicates the total number of intron units found in the sample.

Performance verification of the model using synthetic data

The above analysis was to demonstrate the validity of the local analysis approach and this analysis was to verify that the defined sITH model can indeed measure the ITH of bulk-tumors. We experimented with synthetic data by mixing normal breast tissue data with single-cell breast cancer data. The purpose of this experiment was to test how the sITH of the mixed sample changes as the mixing ratio increases. The evaluation process and its results are as follows.

• First, we collected 112 normal breast tissue RNA-seq data from TCGA-BRCA [40]. Then 39 single cell breast cancer data were collected from another study (SRA accession: SRP159204) [41], where the 39 cells were derived from different clones of a single breast tumor.

• Each RNA-seq data was processed to obtain the splicing junctions, and the samples were combined in various combinations. Our goal at this stage was to specify a predefined level of ITH in each of the synthetic mixture samples.

• We randomly selected normal tissue data from 112 normal tissue pools. Single cells were then selected for mixing. Here, the number of cells represents the ITH level (ie, 1 ~ 39). Selected single cells were mixed in normal tissue at a rate of 1% per cell. The detailed definition of each mixture sample is in Eq 8.

$$MIX(i, j) = NT(j) * (1 - i/100) + \sum_{l=1}^{i} (SC(l, j)/100)$$

Eq 8

The $i$ represents the ITH level we want to specify, and $j$ represents the j-th junction of the mixture sample. $MIX(i, j)$ represents the count of the j-th junction of the resulted mixture sample with i ITH level. $NT(j)$ represents the count of j-th junction in the selected normal tissue sample. $SC(l, j)$ represents the number of j-th junction in the l-th selected single-cell cancer sample. To avoid sampling bias we randomly extracted 10 times at each of 39 ITH levels. Thus, a total of 390 mixture samples were synthesized (10 iterations per 39 ITH levels). In conclusion, samples mixed with more single cells are expected to have a larger ITH by design.
We conducted a correlation analysis between the number of single cells mixed and the sITH value measured in the sample, and the results are discussed in detail in the “Results” section.

Performance verification using xenograft tumor data

The main limitation of the previous synthetic data experiment is the lack of an appropriate evolutionary model in the mixture generation. In this experiment, we used xenograft tumor data (SRA accession: SRP050242) generated by actual clonal evolution [42]. The xenograft mouse model we used is derived from the human breast cancer cell line (MCF10A). Cell lines were treated with HRAS transduction before transplantation to enhance malignancy. After the single-cell origin derived from MCF10A-HRAS was transplanted into immunocompromised mice, the xenograft tissues were cultured until the tumor completely progressed and metastasized. DNA and RNA samples were collected at various points during the process. Therefore, we can compare the ITH from two different molecular domains (genome and spliceome) as the tumor grows. A total of 10 samples were collected while culturing xenograft tissue. They collected two samples for metastatic tissue and one sample for each of the eight-time points.

First, we calculated the sITH for each xenograft tumor sample, using normal breast tissue samples from TCGA as the origin [40]. At this time, 10 normal tissues are randomly selected to avoid selection bias. This comparative analysis is carried out in the following two perspectives. The first is a comparison of the correlation of sITH with the progression of cancer, which indicates time-point provided by the data producers. The second is a comparison of the number of subclones estimated using genomic data, ie, gITH and sITH. These were also measured by data producers using PyClone. PyClone estimates the subclonal structure of each bulk-tumor based on SNV and somatic mutation data. The gITH used in this experiment was the number of estimated subclones. The comparison results are covered in the “Results” section.

Performance verification using TCGA pan-cancer data

Unlike xenograft samples from one common ancestral cell, samples from cancer patients were from a diverse population. This patient-to-patient variation in the genetic background can be a confounding factor that can mask actual ITH. It is also unclear whether the origins of the tissue can affect the results of the analysis because only breast cancer tissues were used in previous experiments. To test whether sITH could overcome potential problems and demonstrate its clinical significance, we performed a comprehensive pan-cancer level experiment using the TCGA pan-cancer dataset [43]. Weinstein et al. aggregated the TCGA pan-cancer data used for the analysis and published them through a web page (https://gdc.cancer.gov/about-data/publications/pancanatlas).

We first collected all the RNA-seq data provided by TCGA pan-cancer. Table 2 summarizes the results of the collection. We then measured sITHs for each RNA-seq sample. There are 9,274 RNA-seq samples of primary tumors. Of the 977 samples, sITH can not be calculated because there is no normal tissue sample matched. Therefore, 8,297 samples are available for sITH. The sITH of each bulk tumor was calculated using corresponding normal tissues. For example, BRCA has 1,093 primary tumors and 112 normal tissues (Table 2). In this case, the sITHs of each tumor sample were calculated by averaging sITH for each of the 112 normal tissues.

The TCGA pan-cancer data validation consists of four steps: 1) comparison of genomic ITH with sITH, 2) comparison of cancer stage with sITH, 3) comparison of survival outcome
with sITH, and 4) comparison of PAM50 subtype and sITH. The comparison results are covered in the “Results” section.

### Results

#### Basic verification of the validity of the model

The Pearson correlation analysis between $ITH_{transcript}$ and $ITH_{intron}$ for 1,000 samples generated with arbitrary heterogeneity levels shows that the two measures have a significant positive correlation ($r = 0.58$, $p = 1.88e-91$) (Fig 3). This means that the local analysis approach, which measures ITH in intron units, can effectively reproduce the values measured in whole-transcripts.

| DISEASE | NT$^1$ | PT$^2$ | sITH$^3$ | gITH$^4$ | STAGE$^5$ | SURVIVAL$^6$ | PAM50$^7$ |
|---------|--------|--------|----------|----------|-----------|-------------|-----------|
| BRCA    | 112    | 1,093  | 1,093    | 1,020    | 1,002     | 325         | 473       |
| KIPAN   | 129    | 889    | 889      | 659      | 632       | 287         | 0         |
| GBMLGG  | 5      | 669    | 669      | 643      | 0         | 274         | 0         |
| STES    | 46     | 599    | 599      | 558      | 142       | 71          | 0         |
| HNSC    | 44     | 520    | 520      | 485      | 422       | 238         | 0         |
| LUAD    | 59     | 515    | 515      | 489      | 487       | 211         | 0         |
| LUSC    | 51     | 501    | 501      | 465      | 464       | 245         | 0         |
| THCA    | 59     | 501    | 501      | 446      | 0         | 0           | 0         |
| PRAD    | 52     | 497    | 497      | 469      | 0         | 0           | 0         |
| BLCA    | 19     | 408    | 408      | 397      | 395       | 210         | 0         |
| COADREAD| 51     | 379    | 379      | 351      | 257       | 91          | 0         |
| LIHC    | 50     | 371    | 371      | 354      | 333       | 155         | 0         |
| CESC    | 3      | 304    | 304      | 291      | 0         | 99          | 0         |
| SARC    | 2      | 259    | 259      | 242      | 0         | 0           | 0         |
| PCPG    | 3      | 179    | 179      | 160      | 0         | 0           | 0         |
| PAAD    | 4      | 178    | 178      | 158      | 66        | 43          | 0         |
| UCEC    | 24     | 176    | 176      | 170      | 0         | 0           | 0         |
| THYM    | 2      | 120    | 120      | 103      | 0         | 0           | 0         |
| SKCM    | 1      | 103    | 103      | 103      | 0         | 0           | 0         |
| CHOL    | 9      | 36     | 36       | 36       | 36        | 19          | 0         |
| OV      | 0      | 303    | 0        | 0        | 0         | 0           | 0         |
| LAML    | 0      | 173    | 0        | 0        | 0         | 0           | 0         |
| TGCT    | 0      | 150    | 0        | 0        | 0         | 0           | 0         |
| MESO    | 0      | 87     | 0        | 0        | 0         | 0           | 0         |
| UVM     | 0      | 80     | 0        | 0        | 0         | 0           | 0         |
| ACC     | 0      | 79     | 0        | 0        | 0         | 0           | 0         |
| UCS     | 0      | 57     | 0        | 0        | 0         | 0           | 0         |
| DLBC    | 0      | 48     | 0        | 0        | 0         | 0           | 0         |
| SUM     | 725(20)| 9,274(28)| 8,297(20)| 7,599(20)| 4,236(11)| 2,268(13)  | 473(1)    |

$^1$ The NT column represents the number of normal tissue samples for each type of cancer.
$^2$ The PT column represents the number of primary tumor RNA-seq samples per cancer type.
$^3$ The sITH column represents the number of samples for which sITH can be calculated.
$^4$ The gITH column represents the number of samples for which both sITH and gITH can be calculated.
$^5$ The STAGE column shows the number of samples with cancer stage information among the samples for which sITH and gITH can be calculated.
$^6$ The SURVIVAL column represents the number of samples with survival outcome information among the samples for which sITH and gITH can be calculated.
$^7$ The PAM50 column shows the number of breast cancer samples with PAM50 label information among the samples for which sITH and gITH can be calculated.

https://doi.org/10.1371/journal.pone.0223520.t002
Performance verification of the model using synthetic data

sITH values were measured for samples made by mixing actual single-cell data with actual breast cancer tissues at a defined ratio and compared to the single-cell blending ratio of each sample. Spearman correlation test showed that the ratio of single cells mixed with sITH was positively correlated ($r = 0.95$, $p = 4.38 \times 10^{-198}$) (Fig 4). This means that the more the single cells are mixed, the higher the sITH is.

One of the problems with this experiment using synthetic data is that an appropriate evolutionary model is not taken into account, which is problematic in the following two points. 1) In this scheme, the ITH level is defined in such a way that different single cells are keep being added to the normal tissue. There is no way to know whether this reflects the actual cancer evolution model. 2) In this scheme, combine single cells is done by simply dividing the junction count, which may be different from the actual experimental results, because there is a limit to the number of reads that can be captured by the RNA-seq technology. These factors may be the cause of the linear and gradual increase of the pattern without the saturation shown in Fig 4 and show the limitations of the experiment using synthetic data.

Performance verification using xenograft tumor data

Spearman correlation showed a positive correlation between sITH and time-point of each sample ($r = 0.88$, $p = 1.39 \times 10^{-33}$). This is plausible because tumor ITH levels are known to increase with cancer progression [42]. Spearman correlation test results of gITH and sITH

Fig 3. A scatter plot showing the correlation between $ITH_{\text{transcript}}$ and $ITH_{\text{intron}}$. The X axis represents $ITH_{\text{transcript}}$ for each sample and the Y axis represents $ITH_{\text{intron}}$.

https://doi.org/10.1371/journal.pone.0223520.g003
measured by genomic data (SNV, somatic mutation) were also correlated for each sample ($r = 0.86, p = 6.09e^{-30}$). This indicates that sITH has a positive correlation with ITH measured at the genome level. The above results are summarized in Fig 5(a) and 5(b).

Performance verification using TCGA pan-cancer data

Comparison of genomic ITH with sITH. A study by Weinstein et al. [43] used ABSOLUTE [13] to calculate the gITH of each TCGA pan-cancer sample. Subclonal genome
fractions were the gITH we use. Of the 8,297 samples, 698 samples did not have a gITH value, so 7,599 samples were used in this analysis (Table 2). The result shows that sITH and gITH are positively correlated (Spearman: \( r = 0.24, p = 1.18\times10^{-99} \)). The scatter plot between sITH and gITH is shown in Fig 6. gITH is the current gold standard for ITH levels in bulk tumors. Therefore, it was used as a reference standard for sITH in all of the following tests.

Significant but not very large correlations between sITH and gITH suggest that ITH definition at the genome level and ITH definition at the spliceome level may be different. This is a phenomenon also mentioned in other transcriptomic ITH (ie tITH) studies [15], suggesting that heterogeneity levels of the same sample can be estimated differently depending on the type of molecule used in the measurement.

**Comparison of cancer stage with sITH.** The cancer stage is a well-known indicator of cancer progression, which is determined based on pathological observations of cancer tissues such as size, location, the extent of invasion, and extent of spread. The level of ITH is generally related to the progression of cancer. Since 3,363 samples out of 7,599 samples did not have cancer stage information, 4,236 samples were used in this analysis (Table 2). Spearman correlation test results showed that sITH of each sample was positively correlated with cancer stage and sITH showed a better correlation with cancer stage than gITH (gITH: \( r = 0.08, p = 4.79\times10^{-07} \), sITH: \( r = 0.27, p = 1.75\times10^{-69} \)) (Fig 7).

**Comparison of survival outcome with sITH.** Overall survival represents survival time after treatment, which in this case implies surgical resection of the tumor. The ITH level is associated with the degree of malignancy of cancer and affects the survival rate of cancer patients [10]. So we tested the association between sITH, gITH and the survival outcome of each sample.
To test the clinical significance of sITH, we performed a survival outcome association test on 5,265 patient RNA-seq samples. First, the patients were divided into two clusters (scikit-learn python 2.7) with K-means clustering using the sITH value of each sample and log-rank test was performed to test the correlation (p = 3.79e-32) (Fig 8a)). The same analysis was performed using gITH (log-rank p = 9.44e-08) (Fig 8b)). The results of the two experiments show that sITH is a much better indicator of survival outcome than gITH. This difference appears to be due to the different types of molecules on which the two indicators are based, suggesting that it is more effective in predicting prognosis using spliceome than genome data.

We tried to create synergy by modeling the two indicators at once. For each sample, a vector with two variables was used as an input and the same analysis was performed. The log-rank test result was p-value 6.28e-08, which showed better performance than the model using the only gITH, but rather a decrease in performance compared to the model using the only sITH. This means that simply combining the two indicators can not create synergy.

Additional analysis has been prepared to help visual understanding. Initially, 7,599 samples were classified into six groups with different survival outcomes. The first five groups were classified by the time of death. For example, the first group contains samples that died in the first year after treatment, and the second group contains samples that died in the second year. The sixth group includes samples reported to be alive for more than 5 years, where the 5-year threshold is based on criteria commonly used to determine cancer remission. As a result, 2,268 samples were classified into six survival groups and the remainder were excluded because they could not be classified into six groups because of the short follow-up period (Table 2).

Fig 9 summarizes the association between sITH, gITH and the survival group of each sample. Both gITH and sITH were significantly correlated with survival groups, whereas sITH showed better association (gITH: r = -0.14, p = 3.10e-11, sITH: r = -0.31, p = 4.72e-53). The result indicates that sample groups having higher lethality have a tendency to have greater sITH. The sample information for each sample group is summarized in Table 2.

Comparison of PAM50 subtype and sITH. The molecular subtype is derived from molecular information in cancer. One of the most studied cancer type in terms of the molecular level is breast cancer, where the well-known molecular subtype system, PAM50, has been broadly used [44]. PAM50 classifies breast tumors into four types such as Luminal A, Luminal B, Her2-enriched, and Basal-like, where the malignancy of tumor increases as the specified...
First, we performed a Kruskal-Wallis test to determine whether the sITH values among the four subtype groups showed significant distributional differences, which showed a significant difference ($p = 5.44e^{-40}$). The same analysis was performed with gITH ($p = 5.09e^{-14}$).

Also, we arranged the samples in the order of Luminal A, Luminal B, Her2-enriched, and Basal-like using the relative malignancy of each subtype. The correlation of the sITH values to the subtype order was then calculated through Spearman correlation. Both ITHs had significant correlation with PAM50 subtype (Fig 10), while sITH showed better association (gITH: $r = 0.36$, $p = 2.48e^{-16}$; sITH: $r = 0.61$, $p = 5.30e^{-49}$). The result indicates that sample groups expected to have greater malignancy by molecular subtypes tend to have greater sITH. The sample information for each sample group is summarized in Table 2.
Discussion

The previous tests answered two important questions. The first is whether sITH can measure the ITH of a bulk tumor, and the second is what is the biological and clinical significance of it. The last important question left would be why sITH works, and how does it work. This can be answered using two concepts. One is genetic diversity, and the other is regression toward the mean.

There is no debate that cancer progression and malignization is the product of somatic evolution, whose most important driver is genetic diversity. Genetic diversity is a critical factor in helping tumors survive in various environments, and the ITH is the very indicator of such diversity. As genomic DNA can be used to estimate genetic diversity, so does spliceome. sITH was designed to capture the increase of spliceomic diversity in each intron. The other important factor is the regression toward the mean. Considering the huge differences between cancer patients, We thought that it might not be easy to pinpoint which intronic loci are important in each patient. So we just averaged the entire intronic loci with expecting to capture the average level of genetic diversity for each bulk-tumor. And the results supported our expectation.

Our study suggests that any type of genetic diversities can be used to predict malignancies of bulk-tumors and it also suggests that integrating various sources of genetic diversities might lead to a more comprehensive model of ITH and a better understanding of malignization.

Fig 10. Boxplot for representing the association of sITH and gITH with PAM50 subtype of each breast cancer sample. a) X-axis indicates the PAM50 subtype of each sample, ordered by known malignancy of each subtype. Y-axis indicates the sITH value of each sample. b) Same as a), except that the Y-axis indicates the gITH value of each sample at this time. The result indicates both sITH and gITH have a significant correlation with PAM50 subtype, while sITH shows better association than gITH. Note that sITH and gITH values are standardized by dividing maximum values among samples for easy understanding of the data distribution.

https://doi.org/10.1371/journal.pone.0223520.g010

Conclusion

Despite studies that show intercellular differences at the spliceome level [25, 26], the clinical effect of sITH has not been studied sufficiently because there was no sITH model. SpliceHetero is a sITH model based on local analysis approach that avoids transcriptome assembly which is not easy in cancer RNA-seq. The proposed model has been extensively tested for its performance using synthetic data, xenograft tumor data, and TCGA pan-cancer data. As a result, sITH has shown a strong association with cancer progression and clonal heterogeneity as well as clinically relevant features such as cancer progression, survival outcome, and PAM50 subtype. Also, the distribution of sITH values within each sample group appears more strict than gITH (Figs 7, 9 and 10). That means sITH is a more consistent indicator than gITH.
The proposed model can help to develop diagnostic and prognostic tools by providing a tool to understand the inherent heterogeneity of cancerous spliceome. The whole process is implemented as a software package and is available free at http://biohealth.snu.ac.kr/software/SpliceHetero. It was implemented in Python 2.7 and tested on CentOS Linux release 7 and Ubuntu 16.04, and 18.04. Lastly, note that all the abbreviations used in this article are listed in Table 3.

### Supporting information

**S1 Table.** The processed sITH values for TCGA pan-cancer dataset. (XLSX)

### Author Contributions

**Conceptualization:** Minsu Kim.

**Data curation:** Minsu Kim.

**Formal analysis:** Minsu Kim.

**Funding acquisition:** Sun Kim.

**Investigation:** Minsu Kim.

**Methodology:** Minsu Kim.
Project administration: Sun Kim.
Software: Minsu Kim.
Supervision: Sun Kim.
Validation: Minsu Kim, Sangseon Lee, Sangsoo Lim.
Visualization: Minsu Kim.
Writing – original draft: Minsu Kim.
Writing – review & editing: Minsu Kim, Sangseon Lee, Sangsoo Lim, Sun Kim.

References

1. Boland CR, Goel A. Somatic evolution of cancer cells. In: Seminars in cancer biology. vol. 15. Elsevier; 2005. p. 436–450.
2. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23–28.
3. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2010; 1805(1):105–117. https://doi.org/10.1016/j.bbcan.2009.11.002
4. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481(7381):306. https://doi.org/10.1038/nature10762 PMID: 22258609
5. Sun Xx, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica. 2015; 36(10):1219. https://doi.org/10.1038/aps.2015.92 PMID: 26388155
6. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017; 168(4):613–628. https://doi.org/10.1016/j.cell.2017.01.018 PMID: 28187284
7. Venet D, Pecasse F, Maenhaut C, Bersini H. Separation of samples into their constituents using gene expression data. Bioinformatics. 2001; 17(suppl_1):S279–S287. https://doi.org/10.1093/bioinformatics/17.suppl_1.s279 PMID: 11473019
8. Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. The Journal of clinical investigation. 2010; 120(2):636–644. https://doi.org/10.1172/JCI40724 PMID: 20101094
9. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, et al. Increased methylation variation in epigenetic domains across cancer types. Nature genetics. 2011; 43(8):768. https://doi.org/10.1038/ng.865 PMID: 21706001
10. Morris LG, Riaz N, Desrichard A, Serbaba Oil Y, Hakimi AA, Makarov V, et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget. 2016; 7(9):10051. https://doi.org/10.18632/oncotarget.7067 PMID: 26840267
11. Yang F, Wang Y, Li Q, Cao L, Sun Z, Jin J, et al. Intratumor heterogeneity predicts metastasis of triple-negative breast cancer. Carcinogenesis. 2017; 38(9):900–909. https://doi.org/10.1093/carcin/bgx071 PMID: 28911002
12. Oh BY, Shin HT, Yun JW, Kim KT, Kim J, Bae JS, et al. Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. Scientific reports. 2019; 9(1):4542. https://doi.org/10.1038/s41598-019-41098-0 PMID: 30872730
13. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nature biotechnology. 2012; 30(5):413. https://doi.org/10.1038/nbt.2203 PMID: 22544022
14. Roth A, Hattia J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nature methods. 2014; 11(4):396. https://doi.org/10.1038/nmeth.2883 PMID: 24633410
15. Park Y, Lim S, Nam JW, Kim S. Measuring intratumor heterogeneity by network entropy using RNA-seq data. Scientific reports. 2016; 6:37767. https://doi.org/10.1038/srep37767 PMID: 27883053
16. Mazor T, Pankov A, Song JS, Costello JF. Intratumoral heterogeneity of the epigenome. Cancer cell. 2016; 29(4):440–451. https://doi.org/10.1016/j.ccell.2016.03.009 PMID: 27070699
17. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic acids research. 2016; 45(D1):D353–D361. https://doi.org/10.1093/nar/gkw1092 PMID: 27899662
18. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes & development. 2010; 24(21):2343–2364. https://doi.org/10.1101/gad.1973010
19. Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. OncoTargets and therapy. 2014; 7:57.

20. Paronetto MP, Passacantilli I, Sette C. Alternative splicing and cell survival: from tissue homeostasis to disease. Cell death and differentiation. 2016; 23(12):1919. https://doi.org/10.1038/cdd.2016.91 PMID: 27689872

21. Read A, Natrajan R. Splicing dysregulation as a driver of breast cancer. Endocrine-related cancer. 2018; 25(9):R467–R478. https://doi.org/10.1530/ERC-18-0068 PMID: 29848666

22. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer cell. 2018; 34(2):211–224. https://doi.org/10.1016/j.ccell.2018.07.001 PMID: 30078747

23. Sveen A, Kilpinen S, Ruusulehto A, Lothe R, Skotheim RI. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene. 2016; 35(19):2413. https://doi.org/10.1038/onc.2015.318 PMID: 26300000

24. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nature Reviews Urology. 2009; 6(8):454. https://doi.org/10.1038/nrurol.2009.125 PMID: 19657379

25. Wan Y, Larson DR. Splicing heterogeneity: separating signal from noise. Genome biology. 2018; 19(1):45. https://doi.org/10.1186/s13059-018-1467-4 PMID: 29986741

26. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, et al. Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature. 2013; 498(7453):236. https://doi.org/10.1038/nature12172 PMID: 23685454

27. Dvinge H, Bradley RK. Widespread intron retention diversifies most cancer transcriptomes. Genome medicine. 2015; 7(1):45. https://doi.org/10.1186/s13073-015-0168-9 PMID: 26113877

28. Eswaran J, Horvath A, Godbole S, Reddy SD, Mudvari P, Ohshiro K, et al. RNA sequencing of cancer reveals novel splicing alterations. Scientific reports. 2013; 3:1689. https://doi.org/10.1038/srep01689 PMID: 23604310

29. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, et al. Systematic analysis of splice-site-creating mutations in cancer. Cell reports. 2018; 23(1):270–281. https://doi.org/10.1016/j.celrep.2018.03.052 PMID: 29617666

30. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190):1396–1401. https://doi.org/10.1126/science.1254257 PMID: 24925914

31. Ardui S, Ameur A, Vermeesch JR, Hestand MS. Single molecule real-time (SMRT) sequencing comes of age: applications and utilities for medical diagnostics. Nucleic acids research. 2018; 46(5):2159–2168. https://doi.org/10.1093/nar/gky066 PMID: 29401301

32. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1):15–21. https://doi.org/10.1093/bioinformatics/bts635 PMID: 23104886

33. Lin J. Divergence measures based on the Shannon entropy. IEEE Transactions on Information theory. 1991; 37(1):145–151. https://doi.org/10.1109/18.61115

34. Joyce JM. Kullback-leibler divergence. In: International Encyclopedia of Statistical Science. Springer; 2011. p. 720–722.

35. Capra JA, Singh M. Predicting functionally important residues from sequence conservation. Bioinformatics. 2007; 23(15):1875–1882. https://doi.org/10.1093/bioinformatics/btm270 PMID: 17519246

36. Azad RK, Li J. Interpreting genomic data via entropic dissection. Nucleic acids research. 2012; 41(1):e23–e23. https://doi.org/10.1093/nar/gks917 PMID: 23036836

37. O’Leary NA, Wright MW, Brister JR, Ciufio S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic acids research. 2015; 44(D1):D733–D745. https://doi.org/10.1093/nar/gkv1189 PMID: 26553804

38. MIT. WgSim; 2011. Available from: https://github.com/lh3/wgsim.

39. Graf JF, Zavodszyk MI. Characterizing the heterogeneity of tumor tissues from spatially resolved molecular measures. PloS one. 2017; 12(11):e0188878. https://doi.org/10.1371/journal.pone.0188878 PMID: 29190747

40. Network CGA, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61. https://doi.org/10.1038/nature11412

41. Zhu D, Zhaozu X, Cui G, Chang S, See YX, Lim MGL, et al. Single-cell transcriptome analysis reveals estrogen signaling augments the mitochondrial folate pathway to coordinately fuel purine and polyamine synthesis in breast cancer cells. bioRxiv. 2018; p. 246363.
42. Chen H, Lin F, Xing K, He X. The reverse evolution from multicellularity to unicellularity during carcinogenesis. Nature communications. 2015; 6:6367. https://doi.org/10.1038/ncomms7367 PMID: 25751731

43. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nature genetics. 2013; 45(10):1113. https://doi.org/10.1038/ng.2764 PMID: 24071849

44. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of clinical oncology. 2009; 27(8):1160. https://doi.org/10.1200/JCO.2008.18.1370 PMID: 19204204